

Serotiny Acquired by Johnson & Johnson

April 1st, 2024

South San Francisco

Serotiny, Inc. has been acquired by Johnson & Johnson. Serotiny will continue to advance its mission to discover new engineered multi-domain proteins for application-tailored cell and gene therapies across a broad spectrum of therapeutic applications. The team is pleased to join Johnson & Johnson Innovative Medicine to continue exploring the potential of the discovery platform as a key capability for creating the next generation of cell and gene therapies.

###

Colin Farlow
CEO & Cofounder
colin.farlow@serotiny.com

Justin Farlow
CTO & Cofounder
justin.farlow@serotiny.com

